BD ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
28全身性アミロイドーシス1
56ベーチェット病5

28. 全身性アミロイドーシス


臨床試験数 : 267 薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01383759
(ClinicalTrials.gov)
June 24, 201127/6/2011Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL AmyloidosisPilot Study of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL AmyloidosisLight Chain Deposition Disease (LCDD or MIDD);Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD);Monoclonal Immunoglobulin Deposition Disease (MIDD);AmyloidosisDrug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/DexamethasoneMemorial Sloan Kettering Cancer CenterMillennium Pharmaceuticals, Inc.Completed18 YearsN/AAll20N/AUnited States

56. ベーチェット病


臨床試験数 : 81 薬物数 : 107 - (DrugBank : 30) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2100052808
2022-01-012021-11-05Mechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote macrophage pyrosis to promote behcet disease progressionMechanism of neutrophils activating cGAS-STING pathway through NETs to activate NLRP3 and promote macrophage pyrosis to promote behcet disease progression Behcet's diseaseControl group:No;Active period Behcet's disease(BD) group:No;Remission period BD group:No;Huadong Hospital of Fudan UniversityNULLRecruiting1855BothControl group:20;Active period Behcet's disease(BD) group:20;Remission period BD group:20;China
2NCT03771768
(ClinicalTrials.gov)
May 25, 20191/12/2018Diode Laser Versus Topical Corticosteroids in Management of Oral Ulcers in Behcet's DiseaseActive Control,Randomized,Double- Blinded Clinical Trial of BDAutoimmune;Behcet SyndromeRadiation: Diode laser 980nm&100 mWatt;Drug: Triamcinolone AcetonideCairo UniversityNULLNot yet recruiting18 Years60 YearsAll38N/ANULL
3NCT01532570
(ClinicalTrials.gov)
January 20126/2/2012Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special LesionsTo Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650Behcet's Disease;Behcet Syndrome;Neuro-Behcet's DiseaseDrug: TA-650Mitsubishi Tanabe Pharma CorporationNULLCompleted16 Years75 YearsAll18Phase 3Japan
4NCT01441076
(ClinicalTrials.gov)
September 201124/9/2011Anakinra for Behcet s DiseaseA Pilot Study of Anakinra in Behcet's Disease (BD)Autoimmune Connective Tissue Disorder;Immune System DiseasesDrug: AnakinraNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NULLCompleted18 Years65 YearsAll6Phase 1/Phase 2United States
5NCT01211977
(ClinicalTrials.gov)
August 27, 201029/9/2010A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's DiseaseA Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD)Muckle Wells Syndrome;Autoinflammatory;Behcet's DiseaseDrug: XOMA 052National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NULLWithdrawn18 YearsN/AAll0Phase 1/Phase 2United States